Abuse Deterrent Pharma, LLC - Jun 9, 2021 Form 4 Insider Report for ACURA PHARMACEUTICALS, INC (ACUR)

Role
10%+ Owner
Signature
/s/ John Schutte, Manager
Stock symbol
ACUR
Transactions as of
Jun 9, 2021
Transactions value $
$6,877,500
Form type
4
Date filed
6/28/2021, 11:00 AM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACUR Common Stock Conversion of derivative security $6.88M +43M $0.16 43M Jun 9, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACUR Convertible Promissory Note Conversion of derivative security $0 -6.88M -100% $0.00* 0 Jun 9, 2021 Common Stock 43M $0.16 Direct F1, F2
holding ACUR Warrant to Purchase Common Stock 1.78M Jun 9, 2021 Common Stock 1.78M $0.53 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The note bears interest at the rate of 7.5% per annum. On the conversion date, all principal and $877,500 of interest under the note was converted into the Issuer's common stock. For each $0.16 converted, AD Pharma received one share of common stock.
F2 This note is convertible, at the election of AD Pharma, at any time prior to repayment of the note and matures on July 1, 2023.